Aspen Neuroscience, Inc S-1/A, filed Oct 22, 2026

Aspen Neuroscience, Inc. (ASPE)

Aspen Neuroscience, Inc. proposes an initial public offering of common stock and plans to list on Nasdaq under “ASPE”; in the Phase 1/2a ASPIRO trial, 15 patients had been dosed as of August 18, 2026, with sasineprocel generally well-tolerated. AI summary